Often, well-intentioned healthcare practitioners do not have access to the current science or clinical best practices supporting safe and efficacious regenerative medicine procedures. Worse, so-called “bad actors” in the field are promoting various therapies and products with little or no scientific basis. As a result, patients often receive “regenerative therapies” resulting in poor outcomes, unreasonably high costs and/or little transparency.
RMSNY is a product-agnostic organization led by internationally recognized scientific and clinical thought leaders. Its clinical members have a simple yet powerful mission – providing their patients with evidence-based, regulatorily-compliant and reasonably-priced regenerative medicine procedures in a transparent manner. Our goal is safe, predictable and demonstrably better outcomes.
RMSNY is led by clinicians and scientists with globally recognized expertise in regenerative medicine.
RMSNY is further supported by an international Clinical/Scientific Advisory Board with a strong track record of independent excellence in the science and clinical translation of regenerative medicine.
J. Peter Rubin, M.D., M.B.A.
Chair, Dept. Of Plastic/Reconstructive Surgery University Of Pittsburgh Medical Center
Christian Jorgensen, M.D., Ph.D.
Director, Institute For Regenerative Medicine And Biotherapy University Of Montpellier
Peter Johnson, M.D.
Co-founder, Pittsburgh Tissue Engineering Initiative University Of Pittsburgh Medical Center
J. William Futrell, M.D.
Former Chair, Dept. Of Plastic/Reconstructive Surgery University Of Pittsburgh Medical Center